[Temporal variations in excess mortality during phase 1 and phase 2 of the COVID-19 epidemic in Italy].

Variazioni temporali della mortalità totale e nei decessi per COVID-19 durante la fase 1 e la fase 2 dell’epidemia in Italia.

Journal

Epidemiologia e prevenzione
ISSN: 1120-9763
Titre abrégé: Epidemiol Prev
Pays: Italy
ID NLM: 8902507

Informations de publication

Date de publication:
Historique:
entrez: 8 1 2021
pubmed: 9 1 2021
medline: 20 1 2021
Statut: ppublish

Résumé

to assess the temporal variation in excess total mortality and the portion of excess explained by COVID-19 deaths by geographical area, gender, and age during the COVID-19 epidemic. descriptive analysis of temporal variations of total excess deaths and COVID-19 deaths in the phase 1 and phase 2 of the epidemic in Italy. 12 Northern cities and 20 Central-Southern cities from December 2019 to June 2020: daily mortality from the National Surveillance System of Daily Mortality (SiSMG) and COVID-19 deaths from the integrated COVID-19 surveillance system. total mortality excess and COVID-19 deaths, defined as deaths in microbiologically confirmed cases of SARS-CoV-2, by gender and age groups. the largest excess mortality was observed in the North and during the first phase of the epidemic. The portion of excess mortality explained by COVID-19 decreases with age, decreasing to 51% among the very old (>=85 years). In phase 2 (until June 2020), the impact was more contained and totally attributable to COVID-19 deaths and this suggests an effectiveness of social distancing measures. mortality surveillance is a sensible information basis for the monitoring of health impact of the different phases of the epidemic and supporting decision making at the local and national level on containment measures to put in place in coming months.

Identifiants

pubmed: 33412815
doi: 10.19191/EP20.5-6.S2.123
pii: 5208
doi:

Types de publication

Journal Article

Langues

ita

Sous-ensembles de citation

IM

Pagination

236-243

Auteurs

Paola Michelozzi (P)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Francesca de' Donato (F)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Manuela De Sario (M)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma; m.desario@deplazio.it.

Matteo Scortichini (M)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Massimo Stafoggia (M)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Fiammetta Noccioli (F)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Xanthi Andrianou (X)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.

Stefano Boros (S)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.

Martina Del Manso (M)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm (Sweden).

Massimo Fabiani (M)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.

Alberto Mateo Urdiales (AM)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.
European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm (Sweden).

Patrizio Pezzotti (P)

Dipartimento malattie infettive, Istituto superiore di sanità, Roma.

Pasqualino Rossi (P)

Direzione generale della prevenzione sanitaria, Ministero della salute, Roma.

Giovanni Rezza (G)

Direzione generale della prevenzione sanitaria, Ministero della salute, Roma.

Giuseppe Costa (G)

Unità di epidemiologia, ASL TO3, Grugliasco.

Marina Davoli (M)

Dipartimento di epidemiologia del Sistema sanitario regionale, Regione Lazio, ASL Roma 1, Roma.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH